title: DNA vaccination of macaques by a full-genome SHIV plasmid that has an IL-2 gene and produces non-infectious virus particles.
abstract: We previously reported that a mutant full-sized plasmid DNA vaccine regime in macaques was effective against a homologous challenge [Akahata W, Ido E, Shimada T, Katsuyama K, Yamamoto H, Uesaka H, et al. DNA vaccination of macaques by a full genome HIV-1 plasmid which produces non-infectious virus particles. Virology 2000;275:116-24; Akahata W, Ido E, Akiyama H, Uesaka H, Enose Y, Horiuchi R, et al. DNA vaccination of macaques by a full genome SHIV-1 plasmid that produces non-infectious virus particles. J Gen Virol 2003;84:2237-44]. In this study, to evaluate the DNA vaccination regime against a heterologous challenge, a novel plasmid named pSHIV-ZF1*IL-2 was constructed. Four monkeys were intramuscularly and intradermally injected four times with the pSHIV-ZF1*IL-2. Vaccinated monkeys were intravenously challenged with a highly pathogenic, heterologous SHIV at 11 weeks post vaccination. All the vaccinated monkeys suppressed the challenge virus rapidly under the detectable level by 16 weeks post challenge. One vaccinated monkey was protected from a loss of CD4+ T cells. These results suggest pSHIV-ZF1*IL-2 alone seems partially effective even against a challenge with a heterologous, pathogenic virus.
authors.affiliation: Laboratory of Primate Model, Experimental Research Center for Infectious Diseases, Institute for Virus Research, Kyoto University, 53 Shogoin-kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan.
authors.forename: Reii
authors.initials: R
authors.lastname: Horiuchi
authors.forename: Wataru
authors.initials: W
authors.lastname: Akahata
authors.forename: Takeo
authors.initials: T
authors.lastname: Kuwata
authors.forename: Yoshimi
authors.initials: Y
authors.lastname: Enose
authors.forename: Eiji
authors.initials: E
authors.lastname: Ido
authors.forename: Hajime
authors.initials: H
authors.lastname: Suzuki
authors.forename: Ariko
authors.initials: A
authors.lastname: Miyake
authors.forename: Naoki
authors.initials: N
authors.lastname: Saito
authors.forename: Kentaro
authors.initials: K
authors.lastname: Ibuki
authors.forename: Toshiyuki
authors.initials: T
authors.lastname: Goto
authors.forename: Tomoyuki
authors.initials: T
authors.lastname: Miura
authors.forename: Masanori
authors.initials: M
authors.lastname: Hayami
mesh_terms: D016915:AIDS Vaccines / Q000276:immunology*; D000818:Animals; D018791:CD4 Lymphocyte Count; D019556:COS Cells; D002522:Chlorocebus aethiops; D005260:Female; D016679:Genome, Viral; D015483:HIV Antibodies / Q000097:blood; D019302:HIV Envelope Protein gp160 / Q000276:immunology; D015497:HIV-1 / Q000276:immunology*; D007376:Interleukin-2 / Q000235:genetics*; D008253:Macaca mulatta; D051379:Mice; D010957:Plasmids / Q000235:genetics*; D015302:Simian Immunodeficiency Virus / Q000276:immunology*; D014611:Vaccination; D019444:Vaccines, DNA / Q000276:immunology*; D014771:Virion / Q000502:physiology*
chemical_list: D016915:AIDS Vaccines; D015483:HIV Antibodies; D019302:HIV Envelope Protein gp160; D007376:Interleukin-2; D019444:Vaccines, DNA